GRCE
Price
$2.99
Change
-$0.08 (-2.61%)
Updated
Aug 28, 04:00 PM (EDT)
Capitalization
42.45M
SLNO
Price
$68.41
Change
+$0.73 (+1.08%)
Updated
Aug 28, 04:59 PM (EDT)
Capitalization
3.7B
69 days until earnings call
Interact to see
Advertisement

GRCE vs SLNO

Header iconGRCE vs SLNO Comparison
Open Charts GRCE vs SLNOBanner chart's image
Grace Therapeutics
Price$2.99
Change-$0.08 (-2.61%)
Volume$100
Capitalization42.45M
Soleno Therapeutics
Price$68.41
Change+$0.73 (+1.08%)
Volume$5.18K
Capitalization3.7B
GRCE vs SLNO Comparison Chart in %
Loading...
GRCE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLNO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GRCE vs. SLNO commentary
Aug 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GRCE is a Hold and SLNO is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 28, 2025
Stock price -- (GRCE: $3.07 vs. SLNO: $67.68)
Brand notoriety: GRCE and SLNO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GRCE: 334% vs. SLNO: 71%
Market capitalization -- GRCE: $42.45M vs. SLNO: $3.7B
GRCE [@Biotechnology] is valued at $42.45M. SLNO’s [@Biotechnology] market capitalization is $3.7B. The market cap for tickers in the [@Biotechnology] industry ranges from $99.27B to $0. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GRCE’s FA Score shows that 0 FA rating(s) are green whileSLNO’s FA Score has 0 green FA rating(s).

  • GRCE’s FA Score: 0 green, 5 red.
  • SLNO’s FA Score: 0 green, 5 red.
According to our system of comparison, GRCE is a better buy in the long-term than SLNO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GRCE’s TA Score shows that 3 TA indicator(s) are bullish while SLNO’s TA Score has 4 bullish TA indicator(s).

  • GRCE’s TA Score: 3 bullish, 7 bearish.
  • SLNO’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, SLNO is a better buy in the short-term than GRCE.

Price Growth

GRCE (@Biotechnology) experienced а -6.12% price change this week, while SLNO (@Biotechnology) price change was -1.83% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.33%. For the same industry, the average monthly price growth was +14.94%, and the average quarterly price growth was +30.68%.

Reported Earning Dates

SLNO is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+2.33% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SLNO($3.7B) has a higher market cap than GRCE($42.5M). SLNO YTD gains are higher at: 50.567 vs. GRCE (-17.914). GRCE has higher annual earnings (EBITDA): -14.8M vs. SLNO (-176.1M). SLNO has more cash in the bank: 287M vs. GRCE (20M). SLNO has higher revenues than GRCE: SLNO (32.7M) vs GRCE (0).
GRCESLNOGRCE / SLNO
Capitalization42.5M3.7B1%
EBITDA-14.8M-176.1M8%
Gain YTD-17.91450.567-35%
P/E RatioN/AN/A-
Revenue032.7M-
Total Cash20M287M7%
Total DebtN/A52.8M-
FUNDAMENTALS RATINGS
GRCE vs SLNO: Fundamental Ratings
GRCE
SLNO
OUTLOOK RATING
1..100
6453
VALUATION
overvalued / fair valued / undervalued
1..100
48
Fair valued
72
Overvalued
PROFIT vs RISK RATING
1..100
5050
SMR RATING
1..100
9598
PRICE GROWTH RATING
1..100
4751
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GRCE's Valuation (48) in the Pharmaceuticals Other industry is in the same range as SLNO (72) in the Medical Specialties industry. This means that GRCE’s stock grew similarly to SLNO’s over the last 12 months.

GRCE's Profit vs Risk Rating (50) in the Pharmaceuticals Other industry is in the same range as SLNO (50) in the Medical Specialties industry. This means that GRCE’s stock grew similarly to SLNO’s over the last 12 months.

GRCE's SMR Rating (95) in the Pharmaceuticals Other industry is in the same range as SLNO (98) in the Medical Specialties industry. This means that GRCE’s stock grew similarly to SLNO’s over the last 12 months.

GRCE's Price Growth Rating (47) in the Pharmaceuticals Other industry is in the same range as SLNO (51) in the Medical Specialties industry. This means that GRCE’s stock grew similarly to SLNO’s over the last 12 months.

GRCE's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as SLNO (100) in the Medical Specialties industry. This means that GRCE’s stock grew similarly to SLNO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GRCESLNO
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
76%
MACD
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 3 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 16 days ago
80%
Bullish Trend 8 days ago
87%
Declines
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 4 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
GRCE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLNO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BCISX18.240.08
+0.44%
Brown Capital Mgmt Intl All Com Instl
COICX18.50N/A
N/A
Calvert International Opportunities C
APGZX120.60N/A
N/A
AB Large Cap Growth Z
JHSGX30.83N/A
N/A
JHancock U.S. Growth R4
RMQAX608.23N/A
N/A
Rydex Monthly Rbl NASDAQ-100® 2x Strt A

GRCE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GRCE has been loosely correlated with IMVT. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if GRCE jumps, then IMVT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GRCE
1D Price
Change %
GRCE100%
-4.51%
IMVT - GRCE
38%
Loosely correlated
+0.66%
SLNO - GRCE
38%
Loosely correlated
-2.77%
CYTK - GRCE
36%
Loosely correlated
-0.94%
SCNI - GRCE
31%
Poorly correlated
-3.90%
ATAI - GRCE
30%
Poorly correlated
-5.38%
More